Wigzell Hans Lennart Rudolf

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
10
Insider Sells Sum
$11.09M

Insider Activity of Wigzell Hans Lennart Rudolf

According to the SEC Form 4 filings, Wigzell Hans Lennart Rudolf, being in a position of

  1. director at Sarepta Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 10500 shares for $1.31M,
    over all time since 2017-11-30, has bought 0 shares, and sold 100501 share for $11.09M.

The largest sale of all time was on 2024-03-08 and amounted to 15000 shares of Sarepta Therapeutics, Inc. for $1.85M.

Biography of Wigzell Hans Lennart Rudolf

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $000
Sells
 $1,310,8201100

Comparison of Insiders on Amount of Buys and Sells

2024-12-12SaleSarepta Therapeutics, Inc.
SRPT
director
10,500
0.011%
$124.84$1.31M-6.99%
2024-03-08SaleSarepta Therapeutics, Inc.
SRPT
director
15,000
0.0159%
$123.25$1.85M+0.78%
2023-08-04SaleSarepta Therapeutics, Inc.
SRPT
director
15,000
0.0163%
$106.72$1.6M+14.59%
2021-03-08SaleSarepta Therapeutics, Inc.
SRPT
director
10,000
0.0126%
$83.51$835,100-5.28%
2020-08-10SaleSarepta Therapeutics, Inc.
SRPT
director
10,000
0.0127%
$159.00$1.59M-43.6%
2020-05-20SaleSarepta Therapeutics, Inc.
SRPT
director
5,000
0.0064%
$150.64$753,210-6.47%
2020-03-04SaleSarepta Therapeutics, Inc.
SRPT
director
5,000
0.0064%
$116.89$584,450+18.33%
2019-05-23SaleSarepta Therapeutics, Inc.
SRPT
director
10,000
0.0137%
$120.00$1.2M-1.34%
2018-11-01SaleSarepta Therapeutics, Inc.
SRPT
director
13,334
0.0106%
$74.72$996,316-14.77%
2017-11-30SaleSarepta Therapeutics, Inc.
SRPT
director
6,667
0.0114%
$55.89$372,619+73.34%
Total: 10
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.